Embolic Stroke of Undetermined Source research hub

EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

This study investigates if empagliflozin, a diabetes drug, can prevent heart rhythm problems (atrial fibrillation) in people who've had a stroke with no clear cause. It uses advanced scans and monitoring to see how the drug affects the heart's upper chambers.